Tags

Type your tag names separated by a space and hit enter

Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma in vivo.
J Bone Oncol 2018; 12:19-22JB

Abstract

The 5TGM1 multiple myeloma transplanted C57BL6/KaLwRij model recapitulates many disease features including monoclonal paraprotein production as well as the development of osteolytic bone lesions. Since a significant association between serum parathyroid hormone PTH variations, bone anabolism and myeloma progression in patients receiving proteasome inhibitors exists, this study investigated the effect of the PTH axis on murine myeloma development in vivo. C57BL6/KaLwRij myeloma-bearing mice underwent thyroparathyroidectomy (TPTX) before and after 5TGM1 cell transplantation. TPTX significantly and permanently inhibited 5TGM1 myeloma cell engraftment and prevented multiple myeloma growth and progression. These data support the hypothesis that the PTH axis is an important mediator of myeloma bone disease.

Authors+Show Affiliations

University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, 4301W Markham #816, Little Rock, AR 72205, USA.University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, 4301W Markham #816, Little Rock, AR 72205, USA.University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, 4301W Markham #816, Little Rock, AR 72205, USA.University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, 4301W Markham #816, Little Rock, AR 72205, USA.Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29556454

Citation

Zangari, Maurizio, et al. "Surgical Thyroparathyroidectomy Prevents Progression of 5TGM1 Murine Multiple Myeloma in Vivo." Journal of Bone Oncology, vol. 12, 2018, pp. 19-22.
Zangari M, Yoo H, Shin IJ, et al. Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma in vivo. J Bone Oncol. 2018;12:19-22.
Zangari, M., Yoo, H., Shin, I. J., Yoon, D., & Suva, L. J. (2018). Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma in vivo. Journal of Bone Oncology, 12, pp. 19-22. doi:10.1016/j.jbo.2018.02.005.
Zangari M, et al. Surgical Thyroparathyroidectomy Prevents Progression of 5TGM1 Murine Multiple Myeloma in Vivo. J Bone Oncol. 2018;12:19-22. PubMed PMID: 29556454.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma in vivo. AU - Zangari,Maurizio, AU - Yoo,Hanna, AU - Shin,Ik Jae, AU - Yoon,Donghoon, AU - Suva,Larry J, Y1 - 2018/02/23/ PY - 2018/01/18/received PY - 2018/02/15/revised PY - 2018/02/22/accepted PY - 2018/3/21/entrez PY - 2018/3/21/pubmed PY - 2018/3/21/medline SP - 19 EP - 22 JF - Journal of bone oncology JO - J Bone Oncol VL - 12 N2 - The 5TGM1 multiple myeloma transplanted C57BL6/KaLwRij model recapitulates many disease features including monoclonal paraprotein production as well as the development of osteolytic bone lesions. Since a significant association between serum parathyroid hormone PTH variations, bone anabolism and myeloma progression in patients receiving proteasome inhibitors exists, this study investigated the effect of the PTH axis on murine myeloma development in vivo. C57BL6/KaLwRij myeloma-bearing mice underwent thyroparathyroidectomy (TPTX) before and after 5TGM1 cell transplantation. TPTX significantly and permanently inhibited 5TGM1 myeloma cell engraftment and prevented multiple myeloma growth and progression. These data support the hypothesis that the PTH axis is an important mediator of myeloma bone disease. SN - 2212-1366 UR - https://www.unboundmedicine.com/medline/citation/29556454/Surgical_thyroparathyroidectomy_prevents_progression_of_5TGM1_murine_multiple_myeloma_in_vivo L2 - https://linkinghub.elsevier.com/retrieve/pii/S2212-1374(18)30008-3 DB - PRIME DP - Unbound Medicine ER -